X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (8) 8
melanoma (8) 8
hematology, oncology and palliative medicine (6) 6
humans (6) 6
metastasis (6) 6
mutation (6) 6
oncology (6) 6
female (5) 5
melanoma - drug therapy (5) 5
studies (5) 5
ipilimumab (4) 4
male (4) 4
treatment outcome (4) 4
young adult (4) 4
adult (3) 3
aged (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
chemotherapy (3) 3
clinical trials (3) 3
cytotoxicity (3) 3
dehydrogenases (3) 3
disease progression (3) 3
disease-free survival (3) 3
drug dosages (3) 3
imidazoles - administration & dosage (3) 3
internal medicine (3) 3
kinases (3) 3
medical prognosis (3) 3
mek inhibition (3) 3
melanoma - mortality (3) 3
middle aged (3) 3
oximes - administration & dosage (3) 3
patients (3) 3
proto-oncogene proteins b-raf - genetics (3) 3
pyridones - administration & dosage (3) 3
pyrimidinones - administration & dosage (3) 3
skin neoplasms - drug therapy (3) 3
survival (3) 3
tumors (3) 3
abridged index medicus (2) 2
adolescent (2) 2
aged, 80 and over (2) 2
analysis (2) 2
antibodies, monoclonal - therapeutic use (2) 2
antigens (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
cancer (2) 2
cancer therapies (2) 2
care and treatment (2) 2
dose-response relationship, drug (2) 2
drug resistance, neoplasm (2) 2
drug therapy (2) 2
drug therapy, combination (2) 2
hospitals (2) 2
immunotherapy (2) 2
intention to treat analysis (2) 2
medicine, general & internal (2) 2
melanoma - genetics (2) 2
metastatic melanoma (2) 2
nivolumab (2) 2
safety (2) 2
skin neoplasms - mortality (2) 2
skin neoplasms - pathology (2) 2
survival analysis (2) 2
time factors (2) 2
[2+2+2] cycloadditions (1) 1
abdominal fat - drug effects (1) 1
abdominal fat - metabolism (1) 1
acids (1) 1
addition reactions (1) 1
adipose tissue (1) 1
administration, oral (1) 1
advanced melanoma (1) 1
alanine (1) 1
alanine transaminase (1) 1
alkenes (1) 1
alkyne cyclotrimerization (1) 1
alkynes (1) 1
alquens (1) 1
alquins (1) 1
androgen excess (1) 1
androgens (1) 1
anti-pd-l1 antibody (1) 1
antibodies, monoclonal - administration & dosage (1) 1
antibodies, monoclonal - adverse effects (1) 1
antibodies, monoclonal, humanized (1) 1
antibodies, monoclonal, humanized - administration & dosage (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
antibodies, monoclonal, humanized - therapeutic use (1) 1
anticoagulants (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
applied chemistry (1) 1
arteriosclerosis (1) 1
article (1) 1
artificial neural-networks (1) 1
assessment (1) 1
assessments (1) 1
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 908 - 918
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 9992, pp. 444 - 451
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9948, pp. 1109 - 1117
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EQ-5D | QUESTIONNAIRE QLQ-C30 | ONCOLOGY | SCORES | RELIABILITY | EUROPEAN-ORGANIZATION | CANCER | VALIDITY | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 954 - 965
Summary Background Addition of a MEK inhibitor to a BRAF inhibitor enhances tumour growth inhibition, delays acquired resistance, and abrogates paradoxical... 
Hematology, Oncology and Palliative Medicine
Journal Article
Journal of the American Chemical Society, ISSN 0002-7863, 9/2010, Volume 132, Issue 35, pp. 12299 - 12306
The present study provides mechanistic details of a mild aromatic C-H activation effected by a copper(II) center ligated in a triazamacrocylic ligand,... 
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2011, Volume 6, Issue 12, p. e29052
Polycystic ovary syndrome (PCOS) is a variable disorder characterized by a broad spectrum of anomalies, including hyperandrogenemia, insulin resistance,... 
PLACEBO | ANDROGEN EXCESS | PLASMA | MULTIDISCIPLINARY SCIENCES | LOW-DENSITY-LIPOPROTEIN | CARDIOVASCULAR-DISEASE | RATS | LOW-DOSE PIOGLITAZONE | RISK | IDENTIFICATION | YOUNG-WOMEN | Multivariate Analysis | Polycystic Ovary Syndrome - blood | Metformin - therapeutic use | Linoleic Acid - metabolism | Humans | Chromatography, Gas | Thiazolidinediones - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Thiazolidinediones - therapeutic use | Polycystic Ovary Syndrome - drug therapy | Spectrometry, Mass, Electrospray Ionization | Lipoproteins - metabolism | Oxidation-Reduction - drug effects | Chromatography, Liquid | Female | Dicarboxylic Acids - blood | Metformin - administration & dosage | Drug Therapy, Combination | Flutamide - therapeutic use | Thiazolidinediones - pharmacology | Biomarkers - metabolism | Polycystic Ovary Syndrome - metabolism | Magnetic Resonance Spectroscopy | Carotid Intima-Media Thickness | Health | Metformin - pharmacology | Linoleic Acid - chemistry | Abdominal Fat - drug effects | Metabolomics - methods | Flutamide - pharmacology | Abdominal Fat - metabolism | Flutamide - administration & dosage | Obesity | Androgens | Flutamide | Blood cholesterol | Stein-Leventhal syndrome | Low density lipoproteins | Atherosclerosis | Insulin resistance | Oxidation-reduction reaction | Hypoglycemic agents | Lipoproteins (low density) | Metabolomics | Adipose tissue | Biomedical research | Nuclear magnetic resonance--NMR | Medical services | Dyslipidemia | Metabolic syndrome | Metabolites | Physiology | Oxidation | Lipoproteins (high density) | Drug dosages | Hypertension | Polycystic ovary syndrome | Internal medicine | Pioglitazone | Markers | Health risks | Particulates | Insulin | Low density lipoprotein | Cholesterol | Endothelium | Acids | Arteriosclerosis | Pharmacy | Metformin | Diabetes | Cardiovascular diseases | Endocrinology | Metabolic disorders | Metabòlits | Ovary diseases | Malalties de l'ovari | Nuclear magnetic resonance | NMR
Journal Article